1 Romano M (2008) Inflammation resolution: does the bone marrow have a say? Am J Hematol 83, 435–436.
2 Calder PC (2006) Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 75, 197–202.
3 Calder PC (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Other Lipid Mediat 77, 327–335.
4 Seki H, Tani Y & Arita M (2009) Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat 89, 126–130.
5 Mataix Verdú, José Francisco & Gil Á (2005) .
6 Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454, 428–435.
7 Singer P, Shapiro H, Theilla M, et al. (2008) Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med 34, 1580–1592.
8 Gil A, María Aguilera C, Gil-Campos M & Cañete R (2007) Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. Br J Nutr 98, Suppl. 1, S121–S126.
9 Basu S (2010) Bioactive eicosanoids: Role of prostaglandin F2α and F2-isoprostanes in inflammation and oxidative stress related pathology. Mols Cells 30, 383–391.
10 Serhan CN, Yacoubian S & Yang R (2008) Anti-inflammatory and pro-resolving lipid mediators. Annu Rev Pathol 3, 279.
11 Calder PC (2006) N-3 Polyunsaturated Fatty Acids, Inflammation, and Inflammatory Diseases. Am J Clin Nutr 83, 1505S–1519S.
12 Charo IF & Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 9, 610–621.
13 Giugliano D, Ceriello A & Esposito K (2006) The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol 15, 677–685.
14 Galli C & Calder PC (2009) Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann Nutr Metab 55, 123–139.
15 Schwab JM & Serhan CN (2006) Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 6, 414–420.
16 Jadad R, Moore R, Carroll D, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1–12.
17 Schulz KF, Altman DG & Moher D (2010) CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 1, 100–107.
18 Pot GK, Brouwer IA, Enneman A, et al. (2009) No effect of fish oil supplementation on serum inflammatory markers and their interrelationships: a randomized controlled trial in healthy, middle-aged individuals. Eur J Clin Nutr 63, 1353–1359.
19 Bouwens M, van de Rest O, Dellschaft N, et al. (2009) Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 90, 415–424.
20 Yusof HM, Miles E & Calder P (2008) Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids 78, 219–228.
21 Schubert R, Kitz R, Beermann C, et al. (2007) Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. Nutrition 23, 724–730.
22 Fujioka S, Hamazaki K, Itomura M, et al. (2006) The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects–A randomized, placebo-controlled, double-blind study. J Nutr Sci Vitaminol 52, 261–265.
23 Mayer K, Gokorsch S, Fegbeutel C, et al. (2003) Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med 15, 1321–1328.
24 Thies F, Miles E, Nebe-von-Caron G, et al. (2001) Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids 36, 1183–1193.
25 Nieman DC, Henson D, McAnulty SR, et al. (2009) N-3 Polyunsaturated Fatty Acids Do Not Alter Immune and Inflammation Measures in Endurance Athletes. Int J Sport Nutr Exerc Metab 19, 536–546.
26 Bloomer RJ, Larson DE, Fisher-Wellman KH, et al. (2009) Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study. Lipids Health Dis 19, 8–36.
27 Cawood AL, Ding R, Napper FL, Young , et al. (2010) Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 20, 252–259.
28 Zhao YT, Shao L, Teng LL, et al. (2009) Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 37, 1831–1841.
29 Tulk HMF & Robinson LE (2009) Modifying the n-6/n-3 polyunsaturated fatty acid ratio of a high-saturated fat challenge does not acutely attenuate postprandial changes in inflammatory markers in men with metabolic syndrome. Metabolism 58, 1709–1716.
30 Browning LM, Krebs JD, Moore CS, et al. (2007) The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 9, 70–80.
31 Engler MM, Engler MB & Malloy MJ (2005) Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study). Am J Cardiol 95, 869–871.
32 Mori T, Woodman RJ, Burke V, et al. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772–781.
33 Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. (2011) Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 93, 243.
34 Bowden RG, Wilson RL, Deike E, et al. (2011) Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract 24, 508–512.
35 Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, et al. (2007) Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology 12, 331–336.
36 Freund-Levi Y, Hjorth E, Lindberg C, et al. (2009) Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dement Geriatr Cogn Disord 27, 481–490.
37 Vedin I, Cederholm T, Freund Levi Y, et al. (2008) Effects of docosahexaenoic acid–rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. Am J Clin Nutr 87, 1616.
38 Barbosa VM, Miles Ea, Calhau C, et al. (2010) Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Crit Care 14, R5.
39 Mayer K, Meyer S, Reinholz-Muhly M, et al. (2003). Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 171, 4837.
40 Wang X, Li W, Li N, et al. (2008) w-3 Fatty Acids–Supplemented Parenteral Nutrition Decreases hyperinflammatory response and attenuates systemic disease sequelae in severe acute pancreatitis: A Randomized and controlled study. Nutr Clin Pract Nutr Clin Pract 32, 236–241.
41 Nilsen DW, Almdahl SM, Svensson B, et al. (1993) Lipopolysaccharide induced monocyte thromboplastin synthesis and coagulation responses in patients undergoing coronary bypass surgery after preoperative supplementation with n-3 fatty acids. Thromb Haemost 20, 900–902.
42 Nieman DC, Henson DA, Gross SJ, et al. (2007) Quercetin reduces illness but not immune perturbations after intensive exercise. Med Sci Sports Exerc 39, 1561–1569.
43 Bruunsgaard H, Pedersen M & Pedersen BK (2001) Aging and proinflammatory cytokines. Curr Opin Hematol 8, 131–136.
44 Toft AD, Thorn M, Ostrowski K, et al. (2000) N-3 polyunsaturated fatty acids do not affect cytokine response to strenuous exercise. J Appl Physiol 89, 2401–2406.
45 Smith LA, Paszkiewicz GM, Hutson AD, et al. (2010) Inflammatory response of lung macrophages and epithelial cells to tobacco smoke: a literature review of ex vivo investigations. Immunol Res 46, 94–126.
46 Vernaglione L, Cristofano C & Chimienti S (2008) Omega-3 polyunsaturated fatty acids and proxies of cardiovascular disease in hemodialysis: a prospective cohort study. J Nephrol 21, 99–105.
47 Saifullah A, Watkins BA, Saha C, et al. (2007) Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients–a pilot study. Nephrol Dial Transplant. 22, 3561–3567.
48 Martin JM & Stapleton RD (2010) Omega-3 fatty acids in critical illness. Nutr Rev 68, 531–541.
49 Bannenberg G & Serhan CN (2010) Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta 1801, 1260–1273.
50 FAO/WHO (2010) .
51 Kris-Etherton PM (2000) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106, 2747–2757.
52 Nälsén C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, et al. (2006) Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans. J Nutr 136, 1222–1228.
53 Higdon JV, Liu J, Du SH, Morrow JD, Ames BN & Wander RC (2000) Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde. Am J Clin Nutr 72, 714–722.